Duet BioSystems

Duet Biosystems is a new decision platform for combination drug development, built on MuSyC, a U.S. patented, peer-reviewed quantitative framework with 200+ citations that independently characterizes changes in drug potency and efficacy as distinct biological phenomena.

 

Combination drug development is one of medicine's most consequential and complex challenges. At $1.1B per drug and 8–12 years to develop, the stakes are high and combinations compound every variable. Every decision about dose, ratio, schedule, sequence, and PK is another place for ambiguity to drive late-stage failure. With only 12.4% of oncology combinations entering Phase I reaching approval, the field needs better tools for making these decisions earlier, safer, and less capital intensive.

Duet's three-layer platform addresses this directly:

Measure with MuSyC: quantify potency and efficacy interactions from combination-response data with precision no single-score tool can match.

Predict with DeepMuSyC: use AI to estimate combination parameters and prioritize candidates before completing experimental screening.

Guide with TEMPO: convert all available evidence into a structured, PK-aware decision: proceed, stop, redesign, or reassess - before a protocol locks in.

Duet has completed NSF Phase I STTR validation, submitted NSF Phase II, submitted MuSyC for drug development tool qualification through FDA ISTAND program, and is actively pursuing FDA BAA funding.